Everolimus Nanoformulation in Biological Nanoparticles Increases Drug Responsiveness in Resistant and Low-Responsive Breast Cancer Cell Lines

Everolimus Nanoformulation in Biological Nanoparticles Increases Drug Responsiveness in Resistant and Low-Responsive Breast Cancer Cell Lines

Everolimus (Eve) is an FDA approved drug that inhibits mammalian target of rapamycin (mTOR). It is employed in breast cancer treatment even if its responsiveness is controversial. In an attempt to increase Eve effectiveness, we have developed a novel Eve nanoformulation exploiting H-ferritin nanocag...

Full description

Bibliographic Details
Main Authors: Arianna Bonizzi, Marta Truffi, Marta Sevieri, Raffaele Allevi, Leopoldo Sitia, Roberta Ottria, Luca Sorrentino, Cristina Sottani, Sara Negri, Elena Grignani, Serena Mazzucchelli, Fabio Corsi
Format: Article
Language:English
Published: MDPI AG 2019-08-01
Series:Pharmaceutics
Subjects:
breast cancer
Everolimus
nanoparticles
H-ferritin
Online Access:https://www.mdpi.com/1999-4923/11/8/384

Internet

https://www.mdpi.com/1999-4923/11/8/384

Similar Items